Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease

Next Previous
Search
Trial Profile

Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Sickle cell anaemia
  • Focus Pharmacokinetics
  • Acronyms HESTIA 1
  • Sponsors AstraZeneca

    • Most Recent Events

    • 06 Nov 2019 Results of HESTIA4 study assessing whether ticagrelor exposure in children less than 24 months old is similar to that in older children and for further dose selection, final PK data from children 2 to <18 years were used from HESTIA1 study, released in 61st Annual Meeting and Exposition of the American Society of Hematology
    • 11 Apr 2019 Results assessing population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease, published in the Clinical Pharmacokinetics
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top